Dark

ACAD
Acadia Pharmaceuticals Inc.
stock NASDAQ

Market Open

Jul 28, 2026 2:17:12 PM EDT

25.90USD+2.009%(+0.51)433,040

25.88Bid 25.90Ask 0.02Spread

Pre-market

Jul 27, 2026 9:27:30 AM EDT

24.88USD+0.161%(+0.04)0

After-hours

Jul 27, 2026 4:00:30 PM EDT

25.39USD+0.020%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

09:15AM EST Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system. RTTNews

08:11AM EST Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders Benzinga

07:41AM EST Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases Benzinga

07:11AM EST Acadia, Stoke Therapeutics To Pursue Multiple RNA-based Treatments For Severe &Rare Genetic Neurodevelopmental Diseases RTTNews

07:00AM EST Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases Business Wire

Jan 5, 2022

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 Benzinga

10:08AM EST What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals Benzinga

07:04AM EST Citigroup Upgrades ACADIA Pharmaceuticals to Buy, Announces $30 Price Target Benzinga

Dec 28, 2021

10:24AM EST $1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much Benzinga

Dec 22, 2021

09:00AM EST Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 Business Wire

08:27AM EST Canaccord Genuity Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $30 Benzinga

Dec 21, 2021

12:49PM EST Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis Benzinga

10:24AM EST B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $32 Benzinga

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021 Benzinga

09:39AM EST Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $30 Benzinga

08:12AM EST The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail Benzinga

07:10AM EST JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $42 Benzinga

07:03AM EST RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $34 Benzinga

06:35AM EST Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral, Announces $28 Price Target Benzinga

Dec 20, 2021

04:10PM EST Acadia Pharma Announces Plan For Resubmission Of SNDA To FDA For NUPLAZID (pimavanserin) RTTNews

04:07PM EST Acadia Pharmaceuticals Announces Plan For A Resubmission Of Its Supplemental New Drug Application To The FDA For NUPLAZID Benzinga

04:05PM EST Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID(r) (pimavanserin) Business Wire

08:16AM EST Arcadia Biosciences Appoints Kevin Comcowich To Interim CEO Benzinga

Dec 17, 2021

03:37PM EST ACADIA Pharmaceuticals Option Alert: Jan 21 $26 Calls Sweep (7) near the Ask: 112 @ $2.551 vs 69 OI; Ref=$25.73 Benzinga

Dec 14, 2021

09:31AM EST Acadia Pharma Announces Promotion Of Mark Schneyer To EVP, CFO RTTNews

09:06AM EST Acadia Pharmaceuticals Announces Promotion Of Mark Schneyer To Executive Vice President, Chief Financial Officer Benzinga

Dec 9, 2021

09:45PM EST Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23 Benzinga

09:45PM EST JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $39 Benzinga

Dec 8, 2021

07:28AM EST Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $28 Benzinga

Dec 7, 2021

11:12AM EST What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals Benzinga

08:37AM EST Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $28 Benzinga

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar Benzinga

08:26AM EST Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $24 Benzinga

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck's HIV Program, Decision Day For Dar Benzinga

07:34AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:02AM EST Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $26 Benzinga

06:59AM EST Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23 Benzinga

06:41AM EST JMP Securities Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $39 Benzinga

Dec 6, 2021

04:09PM EST Acadia Pharmaceuticals Announces Top-line Results From Pivotal Phase 3 Lavender Trial Of Trofinetide in Rett Syndrome; Trofinetide Met Co-Primary Efficacy Endpoints And Key Secondary Endpoint Benzinga

04:05PM EST Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome Business Wire

Dec 1, 2021

09:05AM EST Acadia Highlights The Lancet Psychiatry Publication Of Results From ADVANCE Study Evaluating Pimavanserin Treatment For Negative Symptoms Of Schizophrenia Benzinga

09:00AM EST The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia Business Wire

Nov 16, 2021

09:00AM EST Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly - a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson's Disease Non-Motor Symptoms Business Wire

Nov 9, 2021

11:17AM EST ACADIA Pharmaceuticals: Q3 Earnings Insights Benzinga

11:08AM EST ACADIA Pharmaceuticals Q3 EPS $(0.09) Beats $(0.26) Estimate, Sales $131.60M Beat $127.75M Estimate Benzinga

Nov 8, 2021

04:06PM EST Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results Business Wire

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 2, 2021

11:11AM EDT Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data At Psych Congress 2021 Benzinga

10:24AM EDT Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial Benzinga

09:11AM EDT Acadia Pharma Presents New Dementia-Related Psychosis Real-World Outcomes Data RTTNews

09:00AM EDT Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021 Business Wire

Nov 1, 2021

04:05PM EDT Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial Business Wire

12:17PM EDT Where ACADIA Pharmaceuticals Stands With Analysts Benzinga

08:42AM EDT Guggenheim Upgrades ACADIA Pharmaceuticals to Buy, Announces $23 Price Target Benzinga

Oct 27, 2021

09:00AM EDT Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 Business Wire

Oct 25, 2021

09:09AM EDT Acadia To Present Data On Pimavanserin In Patients With Parkinson's Disease Dementia With Psychosis From HARMONY Trial RTTNews

09:07AM EDT Acadia Pharmaceuticals To Present Data On Pimavanserin In Patients With Parkinson's Disease Dementia With Psychosis From HARMONY Trial At The 14th Clinical Trials On Alzheimer's Disease (CTAD) Conference Benzinga

09:00AM EDT Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson's Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference Business Wire

Oct 14, 2021

11:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 Benzinga

05:58AM EDT Morgan Stanley Downgrades ACADIA Pharmaceuticals to Equal-Weight, Announces $20 Price Target Benzinga

Oct 12, 2021

11:08AM EDT 3 Biotech Stocks to Watch Now Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 2, 2021

09:00AM EDT Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

Sep 1, 2021

04:11PM EDT Acadia Pharmaceuticals EVP And CFO Elena Ridloff To Leave Co. Effective Sept. 10; Mark Schneyer To Become Interim CFO Benzinga

04:05PM EDT Acadia Pharmaceuticals Announces Executive Leadership Change Business Wire

Aug 20, 2021

02:00PM EDT Looking into ACADIA Pharmaceuticals's Return on Capital Employed Benzinga

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

04:05PM EDT Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021 Business Wire

08:29AM EDT Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $27 Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

06:14AM EDT Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $26 Benzinga

05:52AM EDT SVB Leerink Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $28 Benzinga

Aug 4, 2021

04:36PM EDT Acadia Pharmaceuticals Cuts FY21 NUPLAZID Sales Guidance From $510M-$550M To $480-$515M Benzinga

04:35PM EDT ACADIA Pharmaceuticals Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $115.20M Miss $126.15M Estimate Benzinga

04:05PM EDT Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results Business Wire

08:40AM EDT ACADIA Pharmaceuticals Sponsored Study Titled 'An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (DAFFODIL)' Posted To ClinicalTrials.Gov Site Benzinga

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Jul 21, 2021

05:11PM EDT New England Journal Of Medicine Publishes Results From Phase 3 Study Of Pimavanserin In Dementia-Related Psychosis RTTNews

05:06PM EDT Acadia Pharmaceuticals Inc. Highlights Publication Of Results From Phase 3 HARMONY Study In The New England Journal Of Medicine Benzinga

05:05PM EDT The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis Business Wire

11:49AM EDT Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next? Benzinga

09:00AM EDT Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021 Business Wire

Jul 14, 2021

09:19AM EDT Acadia Pharmaceuticals To Present New Scientific Data On Pimavanserin In Neurodegenerative Diseases At Alzheimer's Association International Conference 2021 Benzinga

09:00AM EDT Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer's Association International Conference 2021 (AAIC) Business Wire

Jun 30, 2021

01:10PM EDT ACADIA Pharmaceuticals Option Alert: Jul 16 $27 Calls Sweep (38) near the Ask: 1203 @ $0.922 vs 191 OI; Earnings 8/4 After Close [est] Ref=$24.67 Benzinga

12:55PM EDT ACADIA Pharmaceuticals Option Alert: Jul 16 $27 Calls Sweep (33) near the Ask: 959 @ $0.801 vs 191 OI; Earnings 8/4 After Close [est] Ref=$24.56 Benzinga

Jun 20, 2021

12:20PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 17, 2021

09:36AM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Jun 14, 2021

07:23PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 12, 2021

11:16AM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Jun 10, 2021

10:54AM EDT What 18 Analyst Ratings Have To Say About ACADIA Pharmaceuticals Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021 Benzinga

07:27AM EDT Berenberg Initiates Coverage On ACADIA Pharmaceuticals with Hold Rating, Announces Price Target of $29 Benzinga

Jun 8, 2021

06:24PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 7, 2021

03:05PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Jun 3, 2021

11:26AM EDT NUPLAZID(r) (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders Business Wire

10:01AM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

09:11AM EDT Acadia Says NUPLAZID Efficacy Data From OLE Study Published In Parkinsonism And Related Disorders RTTNews

09:06AM EDT Acadia Pharmaceuticals Highlights Publication Of NUPLAZID In Efficacy Data In Parkinsonism And Related Disorders Journal Benzinga

09:00AM EDT NUPLAZID(r) (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders Business Wire

Jun 2, 2021

05:17PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 26, 2021

04:45PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

May 23, 2021

11:21AM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 20, 2021

09:06PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

May 18, 2021

11:54AM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 14, 2021

11:26PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

May 13, 2021

01:46PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 12, 2021

10:18AM EDT Canaccord Genuity Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $27 Benzinga

May 8, 2021

07:52PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

11:10AM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

May 6, 2021

12:16PM EDT ACADIA Pharmaceuticals Option Alert: Sep 17 $25 Calls at the Ask: 1100 @ $2.55 vs 709 OI; Ref=$20.79 Benzinga

07:52AM EDT Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $29 Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

04:35PM EDT ACADIA Pharmaceuticals Reaffirms FY21 NUPLAZID Net Sales Guidance O $510M-$550M Benzinga

04:34PM EDT ACADIA Pharmaceuticals Q1 EPS $(0.42) Beats $(0.53) Estimate, Sales $106.60M Miss $111.63M Estimate Benzinga

04:10PM EDT Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results Business Wire

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

09:13AM EDT Acadia Pharmaceuticals To Present At BofA Securities 2021 Health Care Conference May 12 And RBC Capital Markets Global Healthcare Conference May 18 Benzinga

09:00AM EDT Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

May 3, 2021

09:52PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 30, 2021

10:13PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Apr 26, 2021

02:42PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 24, 2021

11:17PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

01:46AM EDT LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact PR Newswire

Apr 22, 2021

09:32AM EDT (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed PR Newswire

Apr 21, 2021

09:01AM EDT Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021 Business Wire

Apr 20, 2021

06:08PM EDT Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

03:45PM EDT Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 19, 2021

11:24PM EDT Pomerantz Law Firm Announces the Filing of a Class Action against Acadia PR Newswire

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 7, 2021

08:18AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

06:28AM EDT HC Wainwright & Co. Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $18 Benzinga

Apr 6, 2021

03:40PM EDT Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. GlobeNewswire Inc

10:55AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2021 Benzinga

08:42AM EDT Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28 Benzinga

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

07:55AM EDT Canaccord Genuity Downgrades ACADIA Pharmaceuticals to Hold, Lowers Price Target to $26 Benzinga

07:55AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:52AM EDT Mizuho Downgrades ACADIA Pharmaceuticals to Neutral, Announces $25 Price Target Benzinga

06:50AM EDT Jefferies Downgrades ACADIA Pharmaceuticals to Hold, Lowers Price Target to $21 Benzinga

06:35AM EDT Goldman Sachs Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $25 Benzinga

Apr 5, 2021

09:00PM EDT (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys PR Newswire

02:31PM EDT Mid-Afternoon Market Update: Crude Oil Down 4.5%; Chembio Diagnostics Shares Spike Higher Benzinga

02:16PM EDT Mid-Day Market Update: Leaf Group Jumps Following Acquisition News; ACADIA Pharmaceuticals Shares Slide Benzinga

12:58PM EDT Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30 Benzinga

12:26PM EDT Mid-Day Market Update: Leaf Group Jumps Following Acquisition News; ACADIA Pharmaceuticals Shares Slide Benzinga

10:17AM EDT Mid-Morning Market Update: Markets Open Higher; ISM Services PMI Surges To Record High Benzinga

07:29AM EDT Acadia Pharmaceuticals Inc. (ACAD) said Monday that it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its supplemental New Drug Application or sNDA for NUPLAZID or pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis or DRP. RTTNews

07:22AM EDT Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis Benzinga

06:41AM EDT Acadia Receives CRL From FDA For SNDA For Pimavanserin For Treatment Of Hallucinations And Delusions Associated With DRP RTTNews

06:31AM EDT Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 24, 2021

02:34PM EDT Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. GlobeNewswire Inc

Mar 10, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021 Benzinga

09:02AM EST B of A Securities Downgrades ACADIA Pharmaceuticals to Neutral Benzinga

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

Mar 9, 2021

10:39PM EST (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys PR Newswire

02:31PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 500 Points; INVO Bioscience Shares Spike Higher Benzinga

12:19PM EST Mid-Day Market Update: Gold Rises Over 2%; ACADIA Pharmaceuticals Shares Plunge Benzinga

10:28AM EST Looking Into ACADIA Pharmaceuticals's Return On Capital Employed Benzinga

10:18AM EST Mid-Morning Market Update: Markets Open Higher; Dicks Sporting Goods Profit Beats Views Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021 Benzinga

09:59AM EST Citigroup Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $35 Benzinga

09:29AM EST Guggenheim Downgrades ACADIA Pharmaceuticals to Neutral Benzinga

09:24AM EST Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $40 Benzinga

09:17AM EST Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $50 Benzinga

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

09:16AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

09:16AM EST UPDATE: ACADIA Pharmaceuticals Yesterday Announced Co. Received A Notification From The FDA Indicating 'the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time' Benzinga

09:16AM EST Raymond James Downgrades ACADIA Pharmaceuticals to Outperform, Lowers Price Target to $35 Benzinga

09:15AM EST Stifel Downgrades ACADIA Pharmaceuticals to Hold, Lowers Price Target to $27 Benzinga

09:15AM EST Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $44 Benzinga

06:16AM EST HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $43 Benzinga

Mar 8, 2021

04:22PM EST ACADIA Pharma Shares To Resume Trade At 5:30 p.m. EST Benzinga

04:06PM EST Acadia Pharmaceuticals Provides A Regulatory Update On Its Supplemental New Drug Application For Pimacansein For The Treatment Of Hallucinations And Delusions Associated With Dementia Benzinga

04:05PM EST Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Business Wire

Feb 25, 2021

09:17AM EST ROCE Insights For ACADIA Pharmaceuticals Benzinga

08:36AM EST Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $65 Benzinga

Feb 24, 2021

04:46PM EST Recap: ACADIA Pharmaceuticals Q4 Earnings Benzinga

04:38PM EST ACADIA Sees FY21 Net Sales For NUPLAZID $510M-$550M Benzinga

04:38PM EST ACADIA Pharmaceuticals Q4 EPS $(0.42) Beats $(0.47) Estimate, Sales $121.00M Miss $123.20M Estimate Benzinga

04:06PM EST Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 23, 2021

10:11AM EST A Preview Of ACADIA Pharmaceuticals's Earnings Benzinga

Feb 19, 2021

09:00AM EST Acadia Pharmaceuticals Recognizes National Caregiver's Day with Launch of MoreThanMemoryLoss.com Business Wire

Feb 18, 2021

09:00AM EST Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

Feb 10, 2021

09:00AM EST Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 Business Wire

Jan 27, 2021

04:05PM EST Acadia Pharmaceuticals Announces Commercial Leadership Change Business Wire

Jan 11, 2021

01:31PM EST Shuman Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc. Business Wire

Dec 22, 2020

09:00AM EST Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 Business Wire

Dec 16, 2020

11:59AM EST Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $60 Benzinga

11:25AM EST Benzinga's Top Upgrades, Downgrades For December 16, 2020 Benzinga

10:21AM EST Mizuho Initiates Coverage On ACADIA Pharmaceuticals with Buy Rating, Announces Price Target of $69 Benzinga

Dec 8, 2020

08:35AM EST Cramer Weighs In On Domino's Pizza, Gilead, More Benzinga

Nov 16, 2020

02:24PM EST ACADIA Pharmaceuticals Option Alert: Mar 19 $65 Calls at the Ask: 1250 @ $3.701 vs 22 OI; Ref=$54.6 Benzinga

10:00AM EST Benzinga's Top Upgrades, Downgrades For November 16, 2020 Benzinga

07:14AM EST Raymond James Upgrades ACADIA Pharmaceuticals to Strong Buy, Announces $65 Price Target Benzinga

Nov 10, 2020

09:00AM EST Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 Business Wire

Nov 6, 2020

07:51AM EST Acadia Realty Trust Files For Potential Mixed Shelf Offering; Size Not Disclosed Benzinga

Nov 5, 2020

11:39AM EST ACADIA Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS results. Benzinga

08:03AM EST Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $58 Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

04:36PM EST ACADIA Pharmaceuticals Q3 EPS $(0.54) Misses $(0.38) Estimate, Sales $120.60M Beat $118.82M Estimate Benzinga

04:06PM EST Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results Business Wire

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

09:03AM EDT Acadia Pharma To Present New Scientific Data On Pimavanserin In Neurodegenerative Diseases At Clinital Trials On Alzheimer's Disease Conference Benzinga

09:00AM EDT Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference Business Wire

Oct 21, 2020

04:05PM EDT Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020 Business Wire

Oct 14, 2020

04:05PM EDT The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, "Robin's Wish" Business Wire

Oct 13, 2020

08:06AM EDT Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $57 Benzinga

Oct 1, 2020

09:00AM EDT Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors Business Wire

Sep 5, 2020

08:48AM EDT Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? PR Newswire

Sep 2, 2020

09:00AM EDT ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire

Aug 31, 2020

09:08AM EDT ACADIA Pharmaceuticals Appoints Gudarz Davar EVP And Head Of Research And Development RTTNews

09:00AM EDT ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development Business Wire

Aug 25, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga

09:21AM EDT ACADIA Pharmaceuticals Acquires CerSci Therapeutics For $52.5M, Adds Novel Pain Program to Portfolio Benzinga

09:00AM EDT ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio Business Wire

07:04AM EDT Raymond James Initiates Coverage On ACADIA Pharmaceuticals with Outperform Rating, Announces Price Target of $65 Benzinga

Aug 20, 2020

09:51AM EDT Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga

07:22AM EDT Morgan Stanley Initiates Coverage On ACADIA Pharmaceuticals with Overweight Rating, Announces Price Target of $55 Benzinga

Aug 12, 2020

09:00AM EDT ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020 Business Wire

Aug 6, 2020

10:27AM EDT Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $60 Benzinga

05:07AM EDT SVB Leerink Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $52 Benzinga

Aug 5, 2020

04:59PM EDT ACADIA Pharmaceuticals Q2 EPS $(0.27) Beats $(0.44) Estimate, Sales $110.10M Beat $103.34M Estimate; Narrows, Raises Low End Of FY20 NUPLAZID Net Sales From $420M-$450M To $430M-$450M Benzinga

04:06PM EDT ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results Business Wire

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 29, 2020

09:01AM EDT People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights Business Wire

Jul 22, 2020

04:05PM EDT ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020 Business Wire

Jul 21, 2020

10:43AM EDT ACADIA Pharmaceuticals Inc. (ACAD) shares are down more than 19 percent on Tuesday as its depression drug failed in a phase 3 study. The company said its Nuplazid or pimavanserin did not beat a placebo. RTTNews

10:35AM EDT Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Lowers Price Target to $42 Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Mostly Higher; Coca-Cola Earnings Beat Views Benzinga

09:31AM EDT Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $61 Benzinga

07:46AM EDT RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $55 Benzinga

Jul 20, 2020

04:16PM EDT Acadia Pharmaceuticals Inc. (ACAD) Monday said a late stage study evaluating treatment of depressive disorder didn't achieve primary endpoint. RTTNews

04:06PM EDT ACADIA Says Phase 3 CLARITY Study On Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint RTTNews

04:05PM EDT ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Benzinga